1-4 of 4
Yufen Zhang
Close
Sort by
Journal Articles

Characterization of Response and Transfusion Independence in Patients with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory Acute Myeloid Leukemia Treated with Quizartinib or Salvage Chemotherapy in the Quantum-R Trial

Mark J. Levis, MD, Siddhartha Ganguly, MD, Samer K. Khaled, MD, Alwin Krämer, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Youngsook Choi, MD, Arnaud Lesegretain, Jeanne Mendell, PhD MPH, Derek E. Mires, PharmD, Yufen Zhang, PhD, Jorge E. Cortes, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2599.
https://doi.org/10.1182/blood-2019-124491
Published: 2019
Journal Articles

Clinical Outcomes and Characteristics of Patients (pts) with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial

Siddhartha Ganguly, MD, Jorge E. Cortes, MD, Alwin Krämer, MD, Mark J. Levis, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Nigel H. Russell, MD, Meena Arunachalam, PharmD, Guy Gammon, MBBS, MRCP, Arnaud Lesegretain, Derek E. Mires, PharmD, Ruth Namuyinga, MD MPH, Yufen Zhang, PhD, Samer K. Khaled, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 736.
https://doi.org/10.1182/blood-2019-124504
Published: 2019
Journal Articles

Effect of Co-Mutations and FLT3 -ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Alexander E. Perl, MD, Jorge E. Cortes, MD, Siddhartha Ganguly, MD, Samer K. Khaled, MD, Alwin Krämer, MD, Giovanni Martinelli, MD, Nigel H. Russell, MD, Ken CN Chang, PhD, Derek E. Mires, PharmD, Kazunobu Kato, MD PhD, Yufen Zhang, PhD, Sergey Korkhov, Zhenyu Wang, PhD, Tobias Günnel, PhD, Hiroyuki Sumi, PhD, Takeshi Isoyama, PhD, Arnaud Lesegretain, Flora Berisha, MS, Cedric E. Dos Santos, PhD, Mark J. Levis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 737.
https://doi.org/10.1182/blood-2019-121880
Published: 2019
Journal Articles

Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3 -Internal Tandem Duplication ( FLT3 -ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial

Jorge E. Cortes, MD, Samer K. Khaled, MD, Giovanni Martinelli, MD, Alexander E. Perl, MD, Siddhartha Ganguly, MD, Nigel H. Russell, Alwin Kramer, MD, Herve Dombret, MD, Donna Hogge, Brian A. Jonas, MD PhD, Anskar Y.-H. Leung, MD PhD, Priyanka Mehta, Pau Montesinos, MD PhD, Markus P. Radsak, MD, Simona Sica, MD, Meena Arunachalam, Melissa Holmes, Ken Kobayashi, MD, Ruth Namuyinga, MD MPH, Nanxiang Ge, Antoine Yver, MD, Yufen Zhang, Mark J. Levis, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 563.
https://doi.org/10.1182/blood-2018-99-110439
Published: 2018